2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide
C32H39N7O — CID 156597587
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide
2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide (PubChem CID 156597587) has the molecular formula C32H39N7O and a molecular weight of 537.71 g/mol. Its IUPAC name is 2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide.
Molecular Properties
| Compound Name | 2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide |
|---|---|
| PubChem CID | 156597587 |
| Molecular Formula | C32H39N7O |
| Molecular Weight | 537.71 g/mol |
| Exact Mass | 537.32 |
| IUPAC Name | 2-[4-[2-(azepan-1-yl)-6-methylpyrimidin-4-yl]piperazin-1-yl]-N-(1-benzylindol-5-yl)acetamide |
| SMILES | Cc1cc(N2CCN(CC(=O)Nc3ccc4c(ccn4Cc4ccccc4)c3)CC2)nc(N2CCCCCC2)n1 |
| InChI | InChI=1S/C32H39N7O/c1-25-21-30(35-32(33-25)38-14-7-2-3-8-15-38)37-19-17-36(18-20-37)24-31(40)34-28-11-12-29-27(22-28)13-16-39(29)23-26-9-5-4-6-10-26/h4-6,9-13,16,21-22H,2-3,7-8,14-15,17-20,23-24H2,1H3,(H,34,40) |
| InChIKey | HNVUSFWDXQENHT-UHFFFAOYSA-N |
| XLogP | 4.93 |
| TPSA | 69.53 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 537.71 |
| LogP ≤ 5 | 4.93 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 156597587 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.